Jul. 12 at 2:40 AM
$ABBV $SLS @HboFam
I see you’re in damage control mode now that I caught you in a material misstatement (whether negligent or intentional). Instead of admitting your mistake, you double down on it.
It is beyond dispute that the manufacturer halted the efficacy portion of VIALE-M for slow accrual. That is clearly and unmistakably documented in the medical literature.
Clearly, that reflects very poorly on these BAT drugs and is quite harmful for the bears’ theory that BAT is indeed the reason why the patients in Regal are living so long - a theory I have always disputed. I strongly believe that reason is GPS.
I’ve always maintained the super BAT argument is ludicrous, and that what happened in VIALE-M is supportive of that.
Obviously if Ven/Aza were such a big success somehow the manufacturer would’ve made it right and would’ve come out with the efficacy branch of VIALE-M.
But I also don’t want to misstate the reasons that are in the medical literature as to why the efficacy portion of VIALE-M was halted (the safety portion was completed with finding published earlier this year).
If that study’s IDMC halted it for futility that’s what it would say in the literature. The record doesn’t reflect that.
So I will never overstate the record and misrepresent the medical literature to people here.
Let investors make their own conclusions based on what the record actually states.
I can certainly give them my opinion, which is that the lead BAT arm drugs, Ven and Aza, do not work for AML remission maintenance, which have I said repeatedly.
But I’m not going to misrepresent the reason for the discontinuance of the effficacy branch of VIALE-M just because I have a
$1 million investment in this stock and therefore feel the need to misrepresent and potentially commit securities fraud to enrich myself. No one should.
I’ll leave that to others who might want a date with the SEC, FBI and in federal court. I prefer to have a clear conscience and sleep at night.
Bottom line - the halting of the efficacy branch of VIALE-M is bullish for the GPS arm in Regal.
The stated reason was slow patient accrual - not futility. The IDMC made no such determination in VIALE-M.
And I absolutely believe if those drugs (Ven/Aza) were effective in maintaining remission in AML, the manufacturer would have solved the issue of slow patient accrual, but chose not to.
